Sunday, June 23, 2019 11:33:40 AM
That is why it is significant when Garo said that all of this could be known in as few as "20 to 30 patients". The first patient was dosed 12 weeks ago and there are now 4 sites enrolling patients. If each hospital enrolled one patient a week the enrollment right NOW could be in that 20-30 patient range!
Garo and Jenn were very jacked up during the AGM presentation. My guess is that they already know that this drug is "profoundly effective". More than that I expect that Big Pharma who want to partner also already know this because of their confidentiality agreements.
That is why it is very significant that Garo said that interest in partnering is "at an all time high" and matters are proceeding at "a very, very high pace". My guess is that AGEN 1181 will be the center-piece of multi-Billion dollar partnerships in the near future.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent AGEN News
- Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 05/01/2024 11:30:00 AM
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting • Business Wire • 04/24/2024 02:00:00 PM
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update • Business Wire • 04/23/2024 11:30:00 AM
- Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer • Business Wire • 04/12/2024 11:30:00 AM
- Agenus Announces Reverse Stock Split of Common Stock • Business Wire • 04/05/2024 08:30:00 PM
- Agenus Reports Fourth Quarter and Full Year 2023 Results • Business Wire • 03/14/2024 11:30:00 AM
- Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 • Business Wire • 03/06/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/05/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/29/2024 09:50:48 PM
- Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report • Business Wire • 02/29/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/26/2024 09:24:59 PM
- Agenus to Participate in Leerink Partners Global Biopharma Conference • Business Wire • 02/26/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/15/2024 01:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:00:11 PM
- Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design • PR Newswire (US) • 02/15/2024 12:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:33:12 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 12:00:12 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:11:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:10 PM
- Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 01/31/2024 12:30:00 PM
- Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population • Business Wire • 01/22/2024 02:59:00 PM
- Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population • Business Wire • 01/22/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/05/2024 09:30:00 PM
- Agenus to Participate in B. Riley Healthcare Conference • Business Wire • 01/04/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM